Kelly R. Reveles, Pharm.D., Ph.D., BCPS, BCIDP

Kelly Reveles Profile Pic

Associate Professor of Pharmacotherapy
Pharmacotherapy Division Graduate Advisor

Kelly R. Reveles is an Associate Professor at The University of Texas at Austin College of Pharmacy and an Adjoint Associate Professor at The University of Texas Health Science Center at San Antonio School of Medicine. She received her Doctor of Pharmacy degree from UT Austin and UT Health Science Center San Antonio in 2010. She also completed a multi-disciplinary, multi-institutional Translational Science PhD degree from UT Austin, UT Health Science Center San Antonio, and UT San Antonio in 2014.

Dr. Reveles’ long-term research goal is to reduce the incidence and improve the outcomes of healthcare-associated infections by designing, testing, and implementing effective clinical strategies. Her current research focus is the prevention and treatment of Clostridioides difficile infections and innovative methods to improve the translation of clinical research findings into practice. Her research approach emphasizes multidisciplinary, collaborative research across the translational spectrum, including basic science, preclinical animal studies, human clinical studies, and pharmacoepidemiology studies. She is specifically interested in identifying and implementing clinical strategies for the prevention and treatment of C. difficile infection using national data, the impact of drugs and diseases on the gut microbiome, and the development of microbiome-targeted therapies to mitigate these effects. She is the recipient of a 5-year, $3.4 million NIH/National Institute on Aging R01 grant award evaluating the impact of fecal microbiota transplantation on healthy aging in a marmoset model.

Ambulatory Care Practice & Research Network Paper of the Year
American College of Clinical Pharmacy
October 2021 and October 2019

Outstanding Faculty Advisor
The University of Texas at Austin College of Pharmacy
April 2021

Young Investigator Award
Society of Infectious Diseases Pharmacists
November 2020

Top 10 Faculty for PharmD Student Academic/Professional Impact 
The University of Texas at Austin College of Pharmacy
August 2019

Distinguished Young Alumnus
The University of Texas at Austin College of Pharmacy
September 2019

Preceptor Excellence Award for Interprofessional Education
San Antonio Regional Internship Program
The University of Texas at Austin College of Pharmacy       
July 2019

Introductory Pharmacy Practice Experience (IPPE) Preceptor Excellence Award
The University of Texas at Austin College of Pharmacy
April 2018

NIH/National Institute of Allergy and Infectious Diseases, Clinical Research Loan Repayment Award (Competitive Renewal) (1 L30 TR000604-01) 
August 2017

NIH/National Center for Advancing Translational Science Loan Repayment Award, Clinical Research (Competitive Renewal) (1 L30 TR000604-01) 
June 2014

NIH/National Center for Advancing Translational Science Loan Repayment Award, Clinical Research (1 L30 TR000604-01)
June 2012

Sponsor: NIH/National Institute on Aging (P30AG044271-07)
Principal investigators: Nicolas Musi, MD; Sara Espinoza, MD; Randy Strong, PhD
Role: Co-leader of the Pilot & Exploratory Studies Core
Project title: San Antonio Claude D. Pepper Older Americans Independence Center
Funding period: 06/15/2015-06/30/2025

Sponsor: NIH/National Institute on Aging (U24AG059624-03) competitive pilot grant award
Role: Principal investigator
Project title: Establishing a humanized microbiota-associated mouse colony to study aging 
Funding period: 06/01/2021-05/31/2024

Sponsor: NIH/National Institute on Aging Research Grant Program (1R01AG065546-01)
Role: Multiple principal investigator
Project title: Microbiome-mediated therapies for aging and healthspan in marmosets
Funding period: 09/30/2020-05/31/2025

Sponsor: AstraZeneca
Role: Multiple principal investigator
Project title: Durvalumab impact on non-small cell lung cancer outcomes in veterans   
Funding period: 09/01/2020-08/31/2026

Sponsor: Texas Health & Human Services Commission
Role: Co-investigator
Project title: Texas Targeted Opioid Response – Operation Naloxone Expansion
Funding period: 05/01/2019-08/31/2024

  1. Reveles KR, Yang M, Garcia Horton V, Edwards M, Guo A, Lodise T, Bochan M, Tillotson G, Dubberke E. Economic impact of recurrent Clostridioides difficile infection in the United States: a systematic literature review and cost synthesis. Advances in Therapy Jul 2023;40(7):31-4-3134. DOI: 10.1007/s12325-023-02498-x
  2. Allen P, Johanson K, Reveles KR, Neff L, Lock A. Comparison of droperidol versus haloperidol and lorazepam for acute agitation management in the emergency department. Annals of Pharmacotherapy Mar 2023. DOI: 10.1177/10600280231163192
  3. Shah M, Reveles KR, Moote R, Hand E, Kellogg, Attridge RL, Maselli DJ, Gutierrez GC. Risk of COVID-19 associated pulmonary aspergillosis based on corticosteroid duration in intensive care patients. Open Forum Infectious Diseases Mar 2023;10(3):ofad062, Editor’s Choice Paper. DOI: 10.1093/ofid/ofad062
  4. Nero A, Weber M, Reveles KR, Carreno JJ. Population-based cohort to examine association between geospatial antibiotic factors and urinary tract infection outcomes. American Journal of Infection Control Feb 2023 (online). DOI: 10.1016/j.ajic.2023.01.011
  5. Young EH, Strey KA, Lee GC, Carlson TJ, Koeller JM, Reveles KR. National disparities in antibiotic prescribing by race, ethnicity, age group, and sex in United States ambulatory care visits, 2009 to 2016. Antibiotics Dec 2022;12(1):51. DOI: 10.3390/antibiotics12010051
  6. Shepherd E, Mondy K, Reveles KR, Jaso T, Rose D. Enterococcal bacteremia: a comparison of outcomes with and without infectious diseases consultation. International Journal of Antimicrobial Agents Nov 2022;60(5-6):10665. DOI: 10.1016/j.ijantimicag.2022.106665
  7. Deremiah E, Foster D, Gamboa C, Franco-Martinez, Sponhaltz K, Rippee L, Reveles KR. Effectiveness and safety of high-dose thromboprophylaxis in morbidly obese major trauma patients. Hospital Pharmacy Feb 2023;58(1):92-97. DOI: 10.1177/00185787221111740
  8. Young EH, Strey KA, Lee GC, Carlson TJ, Koeller JM, Reveles KR. Clostridioides difficile infection treatment and outcome disparities in a national sample of United States hospitals. Antibiotics Sep 2022;11(9):1203. DOI: 10.3390/antibiotics11091203
  9. Reveles KR, Frei AL, Strey KA, Young EH. Prevalence and health outcomes of Clostridioides difficile infection during the COVID-19 pandemic in a national sample of United States community hospital systems. Open Forum Infectious Diseases Aug 2022;9(9):ofac441. DOI: 10.1093/ofid/ofac441 
  10. Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel HN, Peckham AM, Chen C, Ganetsky V, Yeung M, Zagorski CM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug and Alcohol Dependence 2022 Aug;237:109518. DOI: 10.1016/j.drugalcdep.2022.109518.
  11. Rose D, Moskhos A, Wibisono A, Reveles KR. Automated susceptibility testing with Vitek 2 associated with reduced vancomycin alternative use for methicillin-resistant Staphylococcus aureus bacteremia. International Journal of Infectious Diseases 2022 Apr;117:179-186. DOI: 10.1016/j.ijid.2022.02.002.
  12. Hintze TD, Small CE, Montgomery J, Reveles KR, Hafeez S, Barthol CA.  Comparison of amantadine, modafinil, and standard of care in the acute treatment of disorders of consciousness following severe traumatic brain injury. Clinical Neuropharmacology Feb 2022;45(1):1-6. DOI: 10.1097/WNF.0000000000000487
  13. Young EH, Pan S, Yap AG, Reveles KR, Bhakta K. Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. PLoS One Aug 2021;16(8):e0255642. DOI: 10.1371/journal.pone.0255642
  14. Evoy KE, Covvey JR, Peckham AM, Reveles KR. Gabapentinoid misuse, abuse, and non-prescribed obtainment in a United States general population sample. International Journal of Clinical Pharmacy Aug 2021;43(4):1055-1064. DOI: 10.1007/s11096-020-01217-8
  15. Das R, Tseng T, Short M, Reveles KR, Wheeler A, Arellanes A, Fongang B, Antonio G, Liss M. Next generation sequencing for microbial analysis to select prophylactic antibiotic selection before urologic stone surgery: a culture change. Open Journal of Urology 2021;11(7):289-304. DOI: 10.4236/oju.2021.117027
  16. Zeidan AR, Strey KA, Vargas MN, Reveles KR. Sexually transmitted infection laboratory testing and education trends in United States outpatient physician offices, 2009-2016. Family Medicine and Community Health Journal Jun 2021;9(3):e000914. DOI: 10.1136/fmch-2021-000914
  17. Hill LG, Loera LJ, Evoy KE, Renfro ML, Torrez SB, Zagorski CM, Perez JC, Jones SM, Reveles KR. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction Jun 2021;116(6):1505-1511. DOI: 10.1111/add.15314
  18. Madrid-Morales J, Sharma A, Reveles KR, Velez-Mejia C, Hopkins T, Yang L, Walter E, Cadena J. Validation of available extended-spectrum beta-lactamase clinical scoring models in predicting drug resistance in patients with enteric gram-negative bacteremia treated at the South Texas Veterans Health Care System. Antimicrobial Agents and Chemotherapy May 2021;65(6):e02562-20. DOI: 10.1128/AAC.02562-20
  19. Kitten AK, Ryan L, Lee GC, Flores BE, Reveles KR. Gut microbiome differences among Mexican Americans with and without type 2 diabetes mellitus. PLoS One May 2021;16(5):e0251245. DOI: 10.1371/journal.pone.0251245
  20. Young EH, Yap AG, Vargas MN, Strey KA, Hao A, Reveles KR. National prevalence of influenza diagnoses and vaccination rates among patients presenting to United States physician offices and hospital outpatient departments, 2009 to 2016. Open Forum Infectious Diseases Mar 2021;8(7):ofab148. DOI: 10.1093/ofid/ofab148

Dr. Reveles’ research on Clostridium difficile infections has recently been highlighted by several prominent media outlets, including The New York Times. Please follow the links below to view several news articles.

The relationship between the gut microbiome and management of C. difficile
Contagion Live

Gut instinct: experts share guidance on emerging C. difficile infection therapeutics
American Society of Health-System Pharmacists 

C. difficile infections fell during pandemic, but patients had higher mortality, costs

Reveles traces rate of hospital infections
Featured article on The University of Texas at Austin College of Pharmacy Home Page

Hospital infections with C. difficile level off
The New York Times

Infamous diarrhea‐causing infections nearly double in U.S. hospitals
Popular Science

Rates of antibiotic‐resistant superbug double over last decade
Aljazeera America

'Deadly diarrhea’ rates nearly doubled in 10 years: study
Association for Professionals in Infection Control and Epidemiology

Contact Information

US Mail Address:
Pharmacotherapy Education & Research Ctr.
University of Texas Health Science Center San Antonio
7703 Floyd Curl Drive – MC 6220
San Antonio, TX 78229-3900